for people ages 18 years and up (full criteria)
study started
estimated completion



This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Arm A will evaluate the safety, tolerability, PK and PD profiles of escalating doses of single-agent TNB-383B, administered once every 3 weeks (Q3W), in approximately 85 subjects. Once the maximum tolerated dose (MTD) or recommended phase 2 dose, (RP2D) is identified in Arm A, Arm B will be initiated to further characterize the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the MTD/RP2D dose of TNB 383B monotherapy in approximately 48 subjects.

Official Title

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma


Multiple Myeloma Neoplasms, Plasma Cell TNB-383B


You can join if…

Open to people ages 18 years and up

  • Subjects with Relapsed/Refractory Multiple Myeloma.
  • Subject has received three or more prior lines of therapy with exposure to a proteasome inhibitor (PI), an immunomodulatory imide (IMiD) and an anti-CD38 monoclonal antibody (e.g., daratumumab).
  • Subject has Measurable Disease, defined as at least 1 of the following:
  • Serum M-protein ≥ 0.5 g/dL (≥ 5 g/L)
  • Urine M-protein ≥ 200 mg / 24h
  • Serum free light chain (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/L) and an abnormal serum FLC ratio (< 0.26 or > 1.65).
  • Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
  • Prior bone marrow transplant is acceptable if subject is > 12 weeks (autologous) or > 1 year (allogeneic) status-post transplantation
  • Subject must have adequate bone marrow function, defined as:
  • absolute neutrophil count (ANC) ≥ 1000/mm3;
  • platelets ≥ 50,000/mm3;
  • hemoglobin ≥ 8.0 g/dL.
  • Subject must have an eGFR ≥ 30 mL/min as estimated by the MDRD formula.
  • Subject must have total bilirubin ≤ 1.5 × upper limit of normal (ULN; except if the subject has a known diagnosis of Gilbert's syndrome, in which case bilirubin must be < 3 x ULN).
  • Serum calcium (corrected for albumin) at or below the ULN range.

You CAN'T join if...

  • Subject has ever received BCMA-targeted therapy. Subjects who have received targeted therapy against non-BCMA targets will not be excluded
  • Subject has a history of central nervous system involvement by their myeloma.
  • Subject has a history of ≥ Grade 3 peripheral neuropathy.
  • Subject has a history of plasma cell leukemia, POEMS syndrome, or amyloidosis.
  • Subject has received any therapy to treat cancer or undergone a major surgical procedure within 21 days, or within 5 half-lives of an anticancer drug, prior to the first dose of study treatment, whichever is shorter.
  • Subject has a history of major cardiac abnormalities.
  • Subject has a known active infection requiring parenteral anti-infective treatment


  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Mayo Clinic-Rochester accepting new patients
    Rochester Minnesota 55905 United States


accepting new patients
Start Date
Completion Date
TeneoOne Inc.
Phase 1
Study Type
Last Updated